<PAGE>
Conformed
Copy
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 26, 1998
------------
CYTOGEN CORPORATION
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 333-02015 22-2322400
--------------- ------------ ------------
(State or other (Commission (IRS Employer
jurisdiction of File No.) Identification No.)
Incorporation or
Organization)
600 College Road East, CN 5308, Princeton, New Jersey 08540-5308
----------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (609) 987-8200
<PAGE>
Item 5. Other Events.
-------------
On May 26, 1998, CYTOGEN Corporation issued the attached press release.
Item 7. Exhibits.
---------
99.1 Press release issued by CYTOGEN Corporation on May 26, 1998
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
CYTOGEN CORPORATION
By /s/ John E. Bagalay, Jr.
----------------------------
Name: John E. Bagalay, Jr.
Title: President and Chief Executive Officer
Date: May 27, 1998
3
<PAGE>
EXHIBIT INDEX
Number Description Page
99.1 Press Release issued by CYTOGEN Corporation on
May 26, 1998 5
4
<PAGE>
FOR IMMEDIATE RELEASE
- -----------------------
Contact: Lili A. Gordon Angela M. Bitting
DuPont Merck Russell-Welsh, Inc.
(978) 671-8924 (650) 312-0700 Ext. 15
DUPONT MERCK AND CYTOGEN ANNOUNCE
CONTINUED COLLABORATION ON QUADRAMET
May 26, 1998 -- The DuPont Merck Pharmaceutical Company and
CYTOGEN Corporation (Nasdaq: CYTO) today announced the withdrawal
of the lawsuit between them regarding the contract under which
DuPont Merck distributes CYTOGEN's cancer pain relief product, Quadramet
(Samarium Sm 153 Lexidronam Injection).
DuPont Merck will continue to manufacture, distribute, and
service Quadramet , and has reaffirmed its previously stated
intention to ensure availability of Quadramet to all eligible
cancer patients. The companies agreed, however, that it is
desirable that a third party be engaged to continue market
development of Quadramet so that it achieves its full market
potential. DuPont Merck, with CYTOGEN's collaboration, will lead
the effort to select an appropriate company for that purpose.
The DuPont Merck Pharmaceutical Company is a worldwide, research-based
pharmaceutical and radiopharmaceutical company established in 1991 as a
partnership between DuPont and Merck and Co. The Company is headquartered
in Wilmington, Delaware; the Radiopharmaceuticals Division is headquartered
in North Billerica, Massachusetts. The Company markets its products under
the DuPont Pharma name.
CYTOGEN is a biopharmaceutical company engaged in the
development, manufacture, and commercialization of products for
the targeted delivery of diagnostics and therapeutic substances
directly to disease sites. CYTOGEN has demonstrated its ability
to develop new technology from early discovery through clinical
development, regulatory approval and commercial scale biologic
manufacturing.
Information in this press release, which is not historical, is
forward looking and involves risks and uncertainties. Actual
results may differ materially, for reasons discussed in CYTOGEN's
filings with the Securities and Exchange Commission, including
risks related to unanticipated expenses which may reduce
CYTOGEN's ability to achieve maximum efficiencies from the change
in business strategies, the ability to find a suitable partner
for further development of the technology, and commercial
acceptance of the CYTOGEN's products.
###
